Knee osteoarthritis with obesity — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• AOD-9604 in knee osteoarthritis

  Growth-hormone C-terminal fragment analogue1 contributing trialfull monograph

  A small trial in knee osteoarthritis reported no significant benefit on the primary endpoint — Small sample.

  Low
• Tirzepatide in knee osteoarthritis

  Dual GIP and GLP-1 receptor agonist (acylated)1 contributing trialfull monograph

  WOMAC pain score improvement exceeding placebo at 68 weeks — Mechanical unloading cannot be separated from any direct effect.

  Low
• BPC-157 in knee osteoarthritis

  Synthetic pentadecapeptide derived from a gastric juice protein sequence0 contributing trialsfull monograph

  No randomised controlled human trial identified — Preclinical only.

  Very low

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology 2001;142(12):5182–5189. doi:10.1210/endo.142.12.8522 · PMID 11713213

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.